Robin L. Goode

1.5k total citations
25 papers, 897 citations indexed

About

Robin L. Goode is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robin L. Goode has authored 25 papers receiving a total of 897 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robin L. Goode's work include Hormonal and reproductive studies (11 papers), Prostate Cancer Treatment and Research (9 papers) and Estrogen and related hormone effects (8 papers). Robin L. Goode is often cited by papers focused on Hormonal and reproductive studies (11 papers), Prostate Cancer Treatment and Research (9 papers) and Estrogen and related hormone effects (8 papers). Robin L. Goode collaborates with scholars based in United States, Switzerland and Canada. Robin L. Goode's co-authors include Larry J. Black, Blake Lee Neubauer, Ann M. McNulty, Rebecca L. Lynch, Jeremy R. Graff, C. David Jones, Karen Huss, Sandaruwan Geeganage, Bruce W. Konicek and Thomas J. Brown and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Endocrinology.

In The Last Decade

Robin L. Goode

25 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin L. Goode United States 14 396 279 185 159 155 25 897
S Ritland United States 12 444 1.1× 208 0.7× 128 0.7× 235 1.5× 83 0.5× 22 965
John E. Monahan United States 12 918 2.3× 223 0.8× 561 3.0× 274 1.7× 192 1.2× 18 1.6k
Bojie Dai United States 18 697 1.8× 115 0.4× 264 1.4× 194 1.2× 92 0.6× 30 1.1k
Jeffrey D. Bray United States 12 441 1.1× 224 0.8× 59 0.3× 139 0.9× 72 0.5× 20 885
Bekir Cinar United States 22 686 1.7× 173 0.6× 424 2.3× 223 1.4× 134 0.9× 29 1.3k
Zeenath Jehan Saudi Arabia 17 731 1.8× 214 0.8× 176 1.0× 390 2.5× 180 1.2× 26 1.2k
Silvia Rita Vitale Italy 16 429 1.1× 87 0.3× 182 1.0× 251 1.6× 112 0.7× 46 978
Demetra Constantinidou United Kingdom 5 1.1k 2.7× 444 1.6× 176 1.0× 495 3.1× 70 0.5× 6 1.4k
Roberto E. Favoni Italy 20 844 2.1× 291 1.0× 356 1.9× 541 3.4× 527 3.4× 39 1.6k
C. K. W. Watts Australia 11 650 1.6× 354 1.3× 155 0.8× 737 4.6× 173 1.1× 15 1.3k

Countries citing papers authored by Robin L. Goode

Since Specialization
Citations

This map shows the geographic impact of Robin L. Goode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin L. Goode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin L. Goode more than expected).

Fields of papers citing papers by Robin L. Goode

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin L. Goode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin L. Goode. The network helps show where Robin L. Goode may publish in the future.

Co-authorship network of co-authors of Robin L. Goode

This figure shows the co-authorship network connecting the top 25 collaborators of Robin L. Goode. A scholar is included among the top collaborators of Robin L. Goode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin L. Goode. Robin L. Goode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yingling, Jonathan M., Jianyong Shou, Xiaoling Xia, et al.. (2006). A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro. Cancer Research. 66. 59–59. 1 indexed citations
2.
McNulty, Ann M., James E. Audia, Kerry G. Bemis, et al.. (2000). Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase. The Journal of Steroid Biochemistry and Molecular Biology. 72(1-2). 13–21. 7 indexed citations
3.
Sutkowski, Debra M., Robin L. Goode, Jack Baniel, et al.. (1999). Growth Regulation of Prostatic Stromal Cells by Prostate-Specific Antigen. JNCI Journal of the National Cancer Institute. 91(19). 1663–1669. 69 indexed citations
4.
Smith, Edward C., Loretta A. McQuaid, Robin L. Goode, et al.. (1998). Synthesis and 5α-reductase inhibitory activity of 8-substituted benzo[ƒ]quinolinones derived from palladium mediated coupling reactions. Bioorganic & Medicinal Chemistry Letters. 8(4). 395–398. 16 indexed citations
5.
Stearns, Mark E., Joy L. Ware, David B. Agus, et al.. (1998). Workgroup 2: Human xenograft models of prostate cancer. The Prostate. 36(1). 56–58. 14 indexed citations
6.
Stearns, Mark E., Joy L. Ware, David B. Agus, et al.. (1998). Workgroup 2: Human xenograft models of prostate cancer. The Prostate. 36(1). 56–58. 1 indexed citations
7.
Kaefer, Martin, James E. Audia, Nicholas Bruchovsky, et al.. (1996). Characterization of type I 5α-reductase activity in DU145 human prostatic adenocarcinoma cells. The Journal of Steroid Biochemistry and Molecular Biology. 58(2). 195–205. 26 indexed citations
8.
Sutkowski, Debra M., et al.. (1996). Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5α-reductase inhibitor. The Prostate. 29(S6). 62–66. 9 indexed citations
9.
Goode, Robin L., et al.. (1995). Prenatal In Vivo Bulbourethral Gland Development Is Not Affected by Prostaglandin E2 Inhibition. Journal of Andrology. 16(1). 5–11. 3 indexed citations
10.
Neubauer, Blake Lee, Kevin L. Best, David F. Counts, et al.. (1995). Raloxifene (LY156758) produces antimetastatic responses and extends survival in the paiii rat prostatic adenocarcinoma model. The Prostate. 27(4). 220–229. 24 indexed citations
11.
Neubauer, Blake Lee, Kevin L. Best, Thomas R. Blohm, et al.. (1993). LY207320 (6‐methylene‐4‐pregnene‐3,20‐dione) inhibits testosterone biosynthesis, androgen uptake, 5α‐reductase, and produces prostatic regression in male rats. The Prostate. 23(3). 181–199. 8 indexed citations
12.
Neubauer, Blake Lee, Kevin L. Best, James A. Clemens, et al.. (1993). Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat. The Prostate. 23(3). 245–262. 24 indexed citations
13.
Neubauer, Blake Lee, Ronald L. Merriman, Kevin L. Best, et al.. (1992). Inhibition of PAIII Rat Prostatic Adenocarcinoma Growth and Metastasis by a New Diarylsulfonylurea Antitumor Agent, LY181984. The Journal of Urology. 147(2). 500–504. 5 indexed citations
14.
Toomey, Richard E., Robin L. Goode, V. Petrow, & Blake Lee Neubauer. (1991). In vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5α‐reductase and comparison of two inhibitors. The Prostate. 19(1). 63–72. 9 indexed citations
15.
Neubauer, Blake Lee, Robin L. Goode, Kevin L. Best, et al.. (1990). Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male rat. Toxicology and Applied Pharmacology. 102(2). 219–232. 9 indexed citations
16.
Neubauer, Blake Lee, et al.. (1989). Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758). The Prostate. 15(3). 273–286. 10 indexed citations
17.
Smith, Gerald F., Blake Lee Neubauer, Kevin L. Best, et al.. (1988). Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Thrombosis Research. 50(1). 163–174. 28 indexed citations
18.
Goodwin, David A., Claude F. Meares, Carol I. Diamanti, et al.. (1981). Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agent.. PubMed. 22(9). 787–92. 25 indexed citations
19.
Black, Larry J. & Robin L. Goode. (1981). EVIDENCE FOR BIOLOGICAL ACTION OF THE ANTIESTROGENS LY117018 AND TAMOXIFEN BY DIFFERENT MECHANISMS. Endocrinology. 109(3). 987–989. 38 indexed citations
20.
Black, Larry J. & Robin L. Goode. (1980). Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sciences. 26(17). 1453–1458. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S Ritland Breakdown of academic impact, for papers by John E. Monahan Breakdown of academic impact, for papers by Bojie Dai Breakdown of academic impact, for papers by Jeffrey D. Bray Breakdown of academic impact, for papers by Bekir Cinar Breakdown of academic impact, for papers by Zeenath Jehan Breakdown of academic impact, for papers by Silvia Rita Vitale Breakdown of academic impact, for papers by Demetra Constantinidou Breakdown of academic impact, for papers by Roberto E. Favoni Breakdown of academic impact, for papers by C. K. W. Watts
Rankless by CCL
2026